 The ardor for shares of AC Immune SA ACIU , Financial has cooled considerably since the companys Aug. 31 announcement of somewhat promising study results for its Alzheimers drug. The Swiss biotechs stock shot up to a 52-week high of 12.61, but has since been halved as investors questioned how meaningful the trial results were. 